CalciMedica (NASDAQ:CALC) Price Target Cut to $10.00 by Analysts at Oppenheimer

CalciMedica (NASDAQ:CALC) had its target price cut by equities research analysts at Oppenheimer from $20.00 to $10.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock.

CALC has been the subject of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of CalciMedica in a research note on Wednesday, January 21st. Wall Street Zen raised shares of CalciMedica to a “sell” rating in a research note on Saturday, January 17th. Finally, HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research note on Thursday, January 29th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $13.00.

CalciMedica Price Performance

CalciMedica stock traded down $0.02 during mid-day trading on Thursday, hitting $0.61. The stock had a trading volume of 202,372 shares, compared to its average volume of 1,637,055. The firm has a market capitalization of $8.75 million, a P/E ratio of -0.38 and a beta of 0.60. The company has a current ratio of 4.03, a quick ratio of 4.04 and a debt-to-equity ratio of 1.39. The firm’s 50 day moving average is $3.08 and its 200 day moving average is $3.36. CalciMedica has a one year low of $0.46 and a one year high of $7.20.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.69) EPS for the quarter. On average, sell-side analysts forecast that CalciMedica will post -2.21 earnings per share for the current fiscal year.

Institutional Trading of CalciMedica

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CALC. Sound View Wealth Advisors Group LLC bought a new position in shares of CalciMedica during the second quarter valued at approximately $32,000. Boothbay Fund Management LLC bought a new stake in shares of CalciMedica during the 4th quarter worth approximately $506,000. Jane Street Group LLC purchased a new position in CalciMedica during the 4th quarter valued at $127,000. Renaissance Technologies LLC grew its position in CalciMedica by 26.1% in the 4th quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after acquiring an additional 18,300 shares during the last quarter. Finally, Cetera Investment Advisers grew its position in CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after acquiring an additional 9,045 shares during the last quarter.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.